Novo Nordisk taps OpenAI

Novo Nordisk said on April 14 it will roll out OpenAI tools across the company to speed work on obesity medicines and patient delivery. (biospace.com) The Danish drugmaker said the partnership will span drug discovery, clinical development, manufacturing, and commercial operations, with “strict data governance and human oversight” built into the arrangement. Novo also said it will use the deal to upskill employees across the business. (biospace.com) In plain terms, Novo is trying to use artificial intelligence as a pattern-finding tool: to sort through research data faster, support decisions during development, and help manage the logistics of getting medicines to patients. The company framed the OpenAI tie-up as part of a push to bring treatments to patients faster. (biospace.com) The move lands in the middle of a crowded obesity-drug race. Novo sells Wegovy, a semaglutide treatment for obesity, while Eli Lilly has been pressing its own products and forcing Novo to defend market share in pills and injections. (bloomberg.com) Novo has paired the OpenAI announcement with fresh commercial steps around Wegovy. Britain’s Medicines and Healthcare products Regulatory Agency said on April 14 it approved a new single-dose 7.2 milligram Wegovy pen for adults with obesity and a body mass index of 30 kilograms per square meter or higher. (gov.uk) The British regulator said the new pen gives patients a single weekly injection at Wegovy’s maximum weight-loss dose. The approval applies to adults with obesity, or adults who are overweight and have at least one weight-related health condition. (gov.uk) In the United States, NovoCare Pharmacy is advertising self-pay Wegovy prices that show how aggressively Novo is trying to widen access outside traditional insurance coverage. Its current materials list $199 a month for new patients on 0.25 milligram and 0.5 milligram doses for two fills through June 30, 2026, and $349 a month for other pen doses. (novocare.com) NovoCare’s pharmacy site says the service ships glucagon-like peptide-1 drugs directly to patients and is aimed at people who do not have insurance or choose to self-pay. That gives Novo another channel to keep patients on branded medicine as competition intensifies. (novocare.com) Novo is also still adding to its obesity pipeline beyond semaglutide. In March 2026, Lexicon Pharmaceuticals and Novo said Novo had started a Phase 1 study of LX9851, an oral non-incretin obesity candidate licensed in 2025. (biospace.com) Taken together, the April 14 announcements show Novo working on two clocks at once: using OpenAI to speed internal work, while adding doses, pricing programs, and new candidates to hold its position in obesity treatment. (biospace.com)